Keywords
Biomarkers
Bioinformatics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: This study aimed to summarize the main evidence highlighting XIST as a modulator of chemotherapy resistance in different tumor types. Methods: A literature review was conducted, selecting studies that correlate XIST with resistance to antineoplastic drugs. Bioinformatics tools, including NcPathName to identify target genes and the CIViC platform to associate these genes with chemoresistance, were used to investigate the role of XIST in different types of cancer. Results: XIST regulates genes associated with chemoresistance, such as PTEN, CDKN1A, CFLAR, MDM2, and ZEB1, which are involved in essential chemoresistance pathways. The interaction between XIST and these genes suggests specific molecular mechanisms behind resistance to agents like 5-fluorouracil in colorectal cancer. The literature suggests that XIST knockdown may be a promising strategy to overcome chemotherapy resistance. Final considerations: This study highlights the importance of exploring lncRNAs like XIST to better understand the mechanisms of chemotherapy resistance and develop more effective therapeutic approaches.
References
CORREA RG, et al. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci Rep, 2012; 32(6): 597-608.
DEB G, et al. EZH2: Not EZHY (Easy) to Deal. Mol Cancer Res, 2014; 12(5): 639-53.
DU P, et al. LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci Rep, 2017; 37(5): BSR20170696.
DUAN A, et al. Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2. J Oncol, 2022; 2022: 4537343.
FANG X, et al. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis, 2020; 11(7): 531.
FUCHS RP, et al. Crosstalk between repair pathways elicits double-strand breaks in alkylated DNA and implications for the action of temozolomide. Elife, 2021; 10: 69544.
GAO C, et al. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer. Breast Cancer Res Treat, 2019; 176(2): 291-301.
HUA G, et al. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3. Pharmacology, 2021; 106(9-10): 498-508.
KUANG Y, et al. The role of lncRNA just proximal to XIST (JPX) in human disease phenotypes and RNA methylation: The novel biomarker and therapeutic target potential. Biomed Pharmacother, 2022; 155: 113753.
LAVOIE H, et al. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol, 2020; 21(10): 607-32.
LI Z, et al. Knockdown de lncRNA-HOTAIR downregula a resistência a drogas de células de câncer de mama à doxorrubicina através da via de sinalização PI3K/AKT/mTOR. Exp Ther Med, 2019; 18: 435-42.
LIU TT, et al. LncRNA XIST acts as a MicroRNA-520 sponge to regulate the Cisplatin resistance in NSCLC cells by mediating BAX through CeRNA network. Int J Med Sci, 2021; 18(2): 419-31.
LUO Y, et al. Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy, 2021; 17(12): 4083-4101.
MA L, et al. Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer. Oncotarget, 2017; 8(3): 4125-35.
MAHESH AN, et al. Cell cycle. Encyclopedia of Toxicology (Fourth Edition), 2023; 2: 667-674.
MENCK K, et al. The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Cells, 2021; 10(1): 142.
OLA MS, et al. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem, 2011; 351(1-2): 41-58.
PENG Y, et al. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol, 2022; 12.
ROY M e MUKHERJEE S. Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac J Cancer Prev, 2014; 15(3): 1403-10.
SÁNCHEZ-TILLÓ E, et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ, 2014; 21(2): 247-57.
SCHOUTEN PC, et al. High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer. Mol Cancer Ther, 2016; 15(1): 190-8.
SETHY C e KUNDU CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother, 2021; 137: 111285.
SHORNING BY, et al. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci, 2020; 21(12): 4507.
SIEGEL RL, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023; 73(1): 17-48.
SUN J, et al. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle, 2017; 16(21): 2100-7.
SUN W, et al. Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol Rep, 2017; 38(6): 3347-54.
TIAN LJ, et al. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p. Med Sci Monit, 2019; 25: 8095-104.
WANG H, et al. Long non-coding RNA XIST modulates cisplatin resistance by altering PDCD4 and Fas-L expressions in human nasopharyngeal carcinoma HNE1 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao, 2019; 39(3): 357-63.
XIA X, et al. LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p/FOXP1 axis. J Gynecol Oncol, 2022; 33(6).
XIAO Y, et al. Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression. Oncotarget, 2017; 8(47): 83171-82.
XU X, et al. Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. Aging (Albany NY), 2020; 12(6): 4711-26.
YAO J, et al. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway. J Cancer Res Clin Oncol, 2017; 143(3): 419-31.
YAROMINA A, et al. Treatment modalities in cancer: An overview. Med Oncol (Northwood Lond Engl), 2020; 37(6): 52.
ZAFAR A, et al. MDM2- an indispensable player in tumorigenesis. Mol Biol Rep, 2023; 50(8): 6871-83.
ZHANG H, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer, 2020; 19(1): 43.
ZHANG M, et al. LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clin Exp Pharmacol Physiol, 2020; 47(8): 1464-72.
ZHANG R, et al. Atractylenolide II reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells. J Cell Mol Med, 2019; 23(5): 3151-65.
ZHANG Z, et al. Autophagy/ferroptosis in colorectal cancer: Carcinogenic view and nanoparticle-mediated cell death regulation. Environ Res, 2023; 238(2):117006.
ZHENG H, et al. LncRNA XIST/miR-137 axis strengthens chemo-resistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. Cancer Biomark, 2021; 30(4): 395-406.
ZHENG HX, et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene, 2013; 32(9): 1183-92.